Glioblastoma（GBM）是成年人中最常见和致命的中枢神经系统恶性肿瘤。包括手术、放疗和化疗在内的传统疗法，在改善患者存活方面的成功率有限。被多种髓样细胞浸润的免疫抑制性肿瘤微环境，已被视为当前治疗的重要障碍。近年来，免疫疗法在血液系统恶性肿瘤和一些实体癌症中取得了巨大成功，因此备受关注，有望用于治疗GBM。在本综述中，我们将介绍不同群体髓样细胞的特征和功能，并介绍目前在GBM免疫疗法方面的临床进展。版权所有©2023黄、张、宗、陈、宗、曾和张。

Glioblastoma (GBM) is the most common and lethal malignant tumor of the central nervous system in adults. Conventional therapies, including surgery, radiotherapy, and chemotherapy, have limited success in ameliorating patient survival. The immunosuppressive tumor microenvironment, which is infiltrated by a variety of myeloid cells, has been considered a crucial obstacle to current treatment. Recently, immunotherapy, which has achieved great success in hematological malignancies and some solid cancers, has garnered extensive attention for the treatment of GBM. In this review, we will present evidence on the features and functions of different populations of myeloid cells, and on current clinical advances in immunotherapies for glioblastoma.Copyright © 2023 Huang, Zhang, Zong, Chen, Zong, Zeng and Zhang.